Germ-specific diagnosis is hard
but necessary
Inappropriate treatment does not prevent hospitalization (40%, of >65 with pneumonia end up hospitalized), and antibiotic misuse leads to antimicrobial resistance
02
Doctors can diagnose pneumonia, but cannot easily identify the underlying microorganism
03
By guidelines, they must prescribe broad-spectrum antibiotics to every patient, despite 50% are actually viral
04
Inappropriate treatment does not prevent the patient from ending up hospitalized (cost > $30k /patient)
01
Respiratory tract infections are the most common (~30%) cause of consultation for primary care worldwide
05
Antibiotic overuse leads to antimicrobial resistance (AMR), #1 world cause of death by 2050
Our Team
Jordan Parker
Position / Role
Max Johnson
Position / Role
Drew Carlyle
Position / Role
Morgan James
Position / Role
About
We are developing a quantitative analysis capable of detecting all microrganisms in both clinical and non-clinical samples, using a fast and cheap technology which can be deployed at the point of care.
How it works
Meet the Founders
Giulio Deangeli
MD, PhD, MBiotech, MMedSci, BEng
Cofounder, CEO
Forbes 30 under 30, North America
PhD on AI, Cambridge
5 degrees in parallel, summa cum laude
Harvard HIP Scholarship, ranked in top 5%
World Vice-Champion Neuroscience, IBB
3 books, papers in Science, Cell, Brain
Fidelius von Rehlingen-Prinz
MD, PhD, MBAc
Cofounder, COO
Advisory board, Kaliber Labs Inc., San Francisco
Medical advisor, Longevital, Munich
CFO, Sustain Surgical Inc., New York
PhD in receptor-specific therapies, Nuremberg
Medical Doctor, summa cum laude
Papers in leading clinical journals
Cristiano Peron
MD, PhD
Cofounder
PhD in translational medicine, Oxford
Clinical Fellow Oxford University Hospital
Fellow, Robert Langer’s family office
Medical Doctor, summa cum laude
Papers in Cell and other journals
How it works
Competitor approaches
Device intrinsic value < $8,000, consumables
< $20-30 /test
Germ-specific diagnosis is hard
but necessary
Inappropriate treatment does not prevent hospitalization (40%, of >65 with pneumonia end up hospitalized), and antibiotic misuse leads to antimicrobial resistance
Antibiotic overuse leads to antimicrobial resistance (AMR), #1 world cause of death by 2050
05
04
Inappropriate treatment does not prevent the patient from ending up hospitalized (cost > $30k /patient)
03
By guidelines, they must prescribe broad-spectrum antibiotics to every patient, despite 50% are actually viral
Doctors can diagnose
pneumonia, but cannot
easily identify the underlying
microorganism
02
01
Respiratory tract infections are the most common (~30%) cause of consultation for primary care worldwide
01
Respiratory tract infections are the most common (~30%) cause of consultation for primary care worldwide
02
Doctors can diagnose
pneumonia, but cannot
easily identify the underlying
microorganism
03
By guidelines, they must prescribe broad-spectrum antibiotics to every patient, despite 50% are actually viral
04
Inappropriate treatment does not prevent the patient from ending up hospitalized (cost > $30k /patient)
01
Respiratory tract infections are the most common (~30%) cause of consultation for primary care worldwide
05
Antibiotic overuse leads to antimicrobial resistance (AMR), #1 world cause of death by 2050
Any sample works
Compatible with respiratory swab, blood, urine, saliva, stool…
Point of care
Can sit on a desk, no lab required
Fast
Result in 10-15 minutes
Cheap
Device intrinsic value
< $10,000, consumables
< $50 /test
Quantitative
Customizable panel of 50+ viruses, bacteria, and fungi in 1 test
Point of care
Can sit on a desk, no lab required
Fast
Result in 10-15 minutes
Cheap
Device intrinsic value
< $10,000, consumables
< $50 /test
Quantitative
Customizable panel of 50+ viruses, bacteria, and fungi in 1 test
One test to rule them all
Competitor approaches
Giulio Deangeli
↗
2024 - Final year PhD candidate, University of Cambridge
2021 - «100 number ones» by Forbes
2020 - 5 university courses in parallel, 30/30 GPA
2018 - Harvard HIP Scholarship, ranked in top 5%
2016 - Amgen Scholarship, Cambridge, ranked #1
2013 - World Vice-Champion Neuroscience, IBB
Author of 2 books; papers in Science, Cell and Brain
MD, PhDc, MBiotech, MMedSci, BEng
Cristiano Peron
↗
2023 - PhD, University of Oxford
2023 - Clinical Fellow Oxford University Hospital
2021 - Old Silver VC Fellow, Boston
2019 - Medical Doctor, summa cum laude
2018 - Armenise-Harvard Fellowship, Harvard University
2017 - IEF Fellowship, Columbia university
Author of papers in Cell and other peer reviewed journals
MD, PhD